Hyperfine interactions in the iron cores from various pharmaceutically important iron-dextran complexes and human ferritin: a comparative study by Mössbauer spectroscopy

Control of the Iron State in Pharmaceuticals Used for Treatment and Prevention of Iron Deficiency Using Mössbauer Spectroscopy

Various iron-containing medicaments, vitamins and dietary supplements are used or developed for treatment and prevention of the iron deficiency anemia which is very dangerous for human and may cause various disorders. From the other hand, blood losses, iron poor diet, microelements (co-factors) deficiency, metabolic failures, absorption problems, etc. can change the iron status and affect the health. These pharmaceuticals contain iron compounds in the ferrous and ferric states. It is known that ferrous salts are more suitable for the intestinal intake than ferric ones. On the other hand, pharmaceutically important ferritin analogues contain ferric hydrous oxides and appear to be effective for both injections and peroral administration. 57Fe Mössbauer spectroscopy is a unique physical technique which allows one to study various iron-containing materials including pharmaceuticals. Therefore, this technique was applied to study iron-containing pharmaceuticals for the analysis of the iron state, identification of ferric and ferrous compounds, revealing some structural peculiarities and for detection of aging processes in relation to the iron compounds. This review considers the main results of a long experience in the study of iron-containing pharmaceuticals by Mössbauer spectroscopy with critical analysis that may be useful for pharmacists, biochemists, biophysicists, and physicians.

Mössbauer Spectroscopy with a High Velocity Resolution in the Studies of Nanomaterials

The present review describes our long experience in the application of Mössbauer spectroscopy with a high velocity resolution (a high discretization of the velocity reference signal) in the studies of various nanosized and nanostructured iron-containing materials. The results reviewed discuss investigations of: (I) nanosized iron cores in: (i) extracted ferritin, (ii) ferritin in liver and spleen tissues in normal and pathological cases, (iii) ferritin in bacteria, (iv) pharmaceutical ferritin analogues; (II) nanoparticles developed for magnetic fluids for medical purposes; (III) nanoparticles and nanostructured FINEMET alloys developed for technical purposes. The results obtained demonstrate that the high velocity resolution Mössbauer spectroscopy permits to excavate more information and to extract more spectral components in the complex Mössbauer spectra with overlapped components, in comparison with those obtained by using conventional Mössbauer spectroscopy. This review also shows the advances of Mössbauer spectroscopy with a high velocity resolution in the study of various iron-based nanosized and nanostructured materials since 2005.

Structural and magnetic study of the iron cores in iron(III)-polymaltose pharmaceutical ferritin analogue Ferrifol®

Iron(III)-polymaltose pharmaceutical ferritin analogue Ferrifol® was investigated by high resolution transmission electron microscopy (HRTEM), X-ray diffraction, thermogravimetry, electron magnetic resonance (EMR) spectroscopy, direct current magnetization measurements and ⁵⁷Fe Mössbauer spectroscopy to get novel information about the structural arrangement of the iron core. The Ferrifol® Mössbauer spectra measured in the range from 295 K to 90 K demonstrated non-Lorentzian two-peak pattern. These spectra were better fitted using a superposition of 5 quadrupole doublets with the same line width. The obtained Mössbauer parameters were different and an unusual line broadening with temperature decrease was observed. Measurements of the Ferrifol® Mössbauer spectra from 60 K to 20 K demonstrated a slow decrease of magnetic relaxation in the iron core. Zero-field-cooled and field-cooled magnetization measurements revealed a blocking temperature at ~33 K and a paramagnetic state of the Ferrifol® iron core at higher temperatures. Isothermal magnetization measurements at 5 K show that the saturation magnetic moment is ~0.31 emu/g. X-band EMR spectroscopy measurements revealed the presence of different magnetic species in the sample. Transmission electron microscopy demonstrated that the size of the iron cores in Ferrifol® is in the range 2-6 nm. The lattice periodicity in these iron cores, measured on the HRTEM images, vary in the range 2.2-2.7 Å. This can be best understood as sets of close packed O(OH) layers in ferrihydrite cores without long range correlation.

Applications of Mössbauer Spectroscopy in Biomedical Research

A brief review on the applications of Mössbauer spectroscopy in biomedical research discusses the results of more than fifty years of experience in this field. Basing on the numerous results the main directions of biomedical applications of Mössbauer spectroscopy are considered as follows: 1) studies of the quantitative changes of iron-containing biomolecules related to pathological processes; 2) studies of the qualitative changes in iron-containing biomolecules related to pathological processes; 3) studies of the effect of various environmental factors (physical, chemical, and biological) on iron-containing biomolecules; 4) studies of metabolic processes by means of analysis of the Mössbauer nuclides pathways in organisms; 5) studies of dynamic processes; 6) studies of pharmaceutical compounds and blood substitutes containing Mössbauer nuclides; 7) miscellaneous studies. Some examples of biomedical research using ⁵⁷Fe, ⁵⁷Co, ¹¹⁹Sn, ¹⁵³Sm, and ¹⁹⁷Au Mössbauer nuclides are presented.

The effect of NaOH and NaClO/NaBr modification on the structural and physicochemical properties of dextran

Dextran was modified at different pH levels by using NaClO/NaBr and also this method was compared with just using NaOH. Then the properties of the products were investigated.

Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products

Iron carbohydrate colloid drug products are intravenously administered to patients with chronic kidney disease for the treatment of iron deficiency anemia. Physicochemical characterization of iron colloids is critical to establish pharmaceutical equivalence between an innovator iron colloid product and generic version. The purpose of this review is to summarize literature-reported techniques for physicochemical characterization of iron carbohydrate colloid drug products. The mechanisms, reported testing results, and common technical pitfalls for individual characterization test are discussed. A better understanding of the physicochemical characterization techniques will facilitate generic iron carbohydrate colloid product development, accelerate products to market, and ensure iron carbohydrate colloid product quality.

Different 57Fe microenvironments in the nanosized iron cores in human liver ferritin and its pharmaceutical analogues on the basis of temperature dependent Mössbauer spectroscopy

Mössbauer spectra of human liver ferritin and its pharmaceutical analogues Ferrum Lek and Maltofer® measured at various temperatures within the range of 295-83K were fitted using five quadrupole doublets related to different ⁵⁷Fe microenvironments in various layers/regions of the ferrihydrite and akaganéite iron cores. The observed anomalous temperature dependences of some Mössbauer parameters were considered as a result of low temperature structural rearrangements in different layers/regions in the iron core.

57Fe Mössbauer spectroscopy and electron paramagnetic resonance studies of human liver ferritin, Ferrum Lek and Maltofer®

A human liver ferritin, commercial Ferrum Lek and Maltofer® samples were studied using Mössbauer spectroscopy and electron paramagnetic resonance. Two Mössbauer spectrometers have been used: (i) a high velocity resolution (4096 channels) at 90 and 295K, (ii) and a low velocity resolution (250 channels) at 20 and 40 K. It is shown that the three studied materials have different superparamagnetic features at various temperatures. This may be caused by different magnetic anisotropy energy barriers, sizes (volume), structures and compositions of the iron cores. The electron paramagnetic resonance spectra of the ferritin, Ferrum Lek and Maltofer® were decomposed into multiple spectral components demonstrating the presence of minor ferro- or ferrimagnetic phases along with revealing marked differences among the studied substances. Mössbauer spectroscopy provides evidences on several components in the measured spectra which could be related to different regions, layers, nanocrystallites, etc. in the iron cores that coincides with heterogeneous and multiphase models for the ferritin iron cores.

Evaluation of the Debye temperature for iron cores in human liver ferritin and its pharmaceutical analogue, Ferrum Lek, using Mössbauer spectroscopy

An iron-polymaltose complex, Ferrum Lek, used as antianemic drug and considered as a ferritin analogue and human liver ferritin were investigated in the temperature range of 295-90K using (57)Fe Mössbauer spectroscopy with a high velocity resolution (in 4096 channels). This study aimed to make a comparison of the Fe atom dynamics in the Ferrum Lek and ferritin iron cores by means of evaluation of the Debye temperature using the temperature dependence of the spectral center shift obtained with two different fitting procedures and the second order Doppler shift approach. The Debye temperature, evaluated as ΘD=502±24K for Ferrum Lek and ΘD=461±16K for human liver ferritin, demonstrated a very small difference in the Fe atom vibrations, reflecting a slightly smaller rigidity in the iron cores in human liver ferritin.

Innovative approaches for demonstration of bioequivalence: the US FDA perspective

In this article, the authors will briefly introduce the general concepts and background of bioavailability and bioequivalence (BE), discuss the conventional method for BE demonstration, and present case examples where novel approaches have been adopted by the US FDA for BE demonstration. Here, 'novel approaches' include unconventional BE studies, as well as statistical criteria for comparison. More specifically, biowaivers, methods to demonstrate BE for highly variable drugs and drug products, and narrow therapeutic index drugs, partial AUCs as additional metrics for some modified-release drug products, methods to demonstrate BE for locally acting gastrointestinal, dermatological, nasal and inhalation products, and non-biological complex drug products, and future perspectives in the field of BE assessment will be discussed. Methods adopted by other agencies, such as European Medicines Agency and Health Canada will be compared with the FDA approaches when appropriate.

Comparative study of the iron cores in human liver ferritin, its pharmaceutical models and ferritin in chicken liver and spleen tissues using Mössbauer spectroscopy with a high velocity resolution

Application of Mössbauer spectroscopy with a high velocity resolution (4096 channels) for comparative analysis of iron cores in a human liver ferritin and its pharmaceutically important models Imferon, Maltofer(®) and Ferrum Lek as well as in iron storage proteins in chicken liver and spleen tissues allowed to reveal small variations in the (57)Fe hyperfine parameters related to differences in the iron core structure. Moreover, it was shown that the best fit of Mössbauer spectra of these samples required different number of components. The latter may indicate that the real iron core structure is more complex than that following from a simple core-shell model. The effect of different living conditions and age on the iron core in chicken liver was also considered.

Mössbauer spectroscopy with a high velocity resolution in the study of iron-containing proteins and model compounds

Mössbauer spectroscopy with a high velocity resolution was used for comparative studies of human adult, rabbit and pig oxyhemoglobins, human liver ferritin and its pharmaceutically important models Imferon and Maltofer(®) as well as liver and spleen tissues from normal and lymphoid leukemia chicken. These studies revealed small variations of Mössbauer hyperfine parameters which were related to small variations of iron electronic structure and stereochemistry in these samples.

Determination of the iron state in ferrous iron containing vitamins and dietary supplements: Application of Mössbauer spectroscopy

Determination of the iron state in commercially manufactured iron containing vitamins and dietary supplements is important for evaluation of pharmaceuticals quality. Mössbauer (nuclear gamma-resonance) spectroscopy was used for analyzing the iron state in commercial pharmaceutical products containing ferrous fumarate (FeC(4)H(2)O(4)), ferrous sulfate (FeSO(4)), ferrous bisglycinate chelate (Ferrochel) and ferrous iron (hydrolyzed protein chelate). Mössbauer parameters and the iron states were determined for iron compounds in the studied pharmaceuticals. Various ferric and ferrous impurities were found in all of the commercial products. The quantities of ferric impurities exceeded the FDA limitation of 2% in products containing ferrous fumarate. The quantities of ferric impurities exceeded 58% and 30% in products containing ferrous bisglycinate chelate and ferrous iron (hydrolyzed protein chelate), respectively. The presence of ferrous and ferric impurities was not related to the ageing of the vitamins and dietary supplements. Two pharmaceutical products contained major iron compounds, the Mössbauer parameters of which did not correspond to the ferrous fumarate or ferrous bisglycinate chelate claimed by the manufacturer.

Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations

Intravenous iron therapy is used to treat anemia associated with chronic kidney disease. The chemical structures of parenteral iron agents have not been characterized in detail, and correlations between structure, efficiency of iron delivery, and toxicity via catalysis of oxygen-derived free radical creation remain to be established. In this study, two formulations of parenteral iron have been characterized by absorption spectroscopy, X-ray diffraction analysis (XRD), transmission electron microscopy (TEM), atomic force microscopy (AFM), and elemental analysis. The samples studied were Venofer (Iron Sucrose Injection, USP) and Ferrlecit (Sodium Ferric Gluconate in Sucrose Injection). The 250-800-nm absorption spectra and the XRD patterns showed that both formulations contain a mineral core composed of iron oxyhydroxide in the beta-FeOOH mineral polymorph known as akaganeite. This was further confirmed for each formulation by imaging using TEM and AFM. The average core size for the nanoparticles, after dialysis to remove unbound or loosely bound carbohydrate, was approximately 3+/-2 nm for the iron-sucrose, and approximately 2+/-1 nm for the iron-gluconate. Each of the nanoparticles consists of a mineral core, surrounded by a layer of bound carbohydrate. The overall diameter of the average bead in the dialyzed preparations was approximately 7+/-4 nm for the iron-sucrose, and 3+/-1 nm for the iron-gluconate. Undialyzed preparations have particles with larger average sizes, depending on the extent of dilution of unbound and loosely bound carbohydrate. At a dilution corresponding to a final Fe concentration of 5 mg/mL, the average particle diameter in the iron-sucrose formulation was approximately 22+/-9 nm, whereas that of the iron-gluconate formulation was approximately 12+/-5 nm.

Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra

The possible role of iron in the degeneration of nervous cells in Parkinson's disease (PD) was studied with the use of Mössbauer spectroscopy (MS) and enzyme-linked immunoabsorbent assay (ELISA). Mössbauer data were obtained at 90 and 4.1 K from 21 samples of control and 9 samples of parkinsonian substantia nigra (SN). Mössbauer spectra were very similar to those observed in ferritin. Small differences were detected between the spectra obtained from PD and from control SN, and could be due to a slight difference in the composition of the ferritin-like iron cores or due to the presence of about 8% of non-ferritin-like iron in parkinsonian SN. ELISA studies from 11 controls and 6 parkinsonian SN showed a decrease in the concentration of L-chains in wet tissues of PD-SN compared to control SN. The decrease in the amount of L subunits may correspond to a decreased ability of this ferritin to keep iron in a safe form. Iron released from ferritin or neuromelanin (NM) may be the source of such iron, which may cause the difference in the Mössbauer spectra and may trigger oxidative stress leading to cell death.

Study of the relationship of small variations of the molecular structure and the iron state in iron containing proteins by Mössbauer spectroscopy: biomedical approach

This review considers the results of experimental Mössbauer studies and theoretical calculations of the effect of small variations of protein molecular structure on the iron electronic structure and stereochemistry in order to understand the proteins structural heterogeneity and functional variety. Structural changes in iron containing proteins during various diseases are also considered. These results show the relationship of the small structural variations and Mössbauer parameters of iron containing proteins and demonstrate the possibilities of Mössbauer spectroscopy to obtain new information at the molecular level in biomedical research.

Mössbauer spectroscopy in biomedical research

This work discusses the main directions and results of the application of Mössbauer spectroscopy of iron containing species in biomedical research. These studies demonstrate the wide possibilities of Mössbauer spectroscopy to obtain physical parameters and information about the iron electronic structure in normal and pathological biomolecules, model compounds and pharmaceutical samples as well as about qualitative and quantitative changes of iron containing biomolecules during pathological processes or the effect of environmental factors. The results obtained may be useful for further understanding of the molecular nature of diseases and pathological processes.